2. Search Result
Search Result
Results for "

wound closure

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

2

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6871
    Abietic acid
    3 Publications Verification

    		 Bacterial IKK Ferroptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
    Abietic acid
  • HY-134570
    ZINC40099027
    3 Publications Verification

    		 FAK Metabolic Disease Inflammation/Immunology
    ZINC40099027 is a selective FAK activator. ZINC40099027 promotes FAK phosphorylation, without activating its paralogs Pyk2 and Src. ZINC40099027 promotes the wound closure of human intestinal epithelial monolayers and the healing of mouse ulcers by activating FAK. ZINC40099027 can be used for diseases related to gastrointestinal mucosal injury research .
    ZINC40099027
  • HY-N9445
    Lacto-N-neotetraose

    LNnT

    		 Endogenous Metabolite TNF Receptor Inflammation/Immunology
    Lacto-N-neotetraose (LNnT) is an endogenous metabolite. Lacto-N-neotetraose can inhibit TNF-α induced IL-8 secretion in immature epithelial cells. Lacto-N-neotetraose has anti-inflammatory avtivity, and can improve the wound closure .
    Lacto-N-neotetraose
  • HY-122124
    CAY10583

    		Leukotriene Receptor Inflammation/Immunology
    CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds .
    CAY10583
  • HY-W250121
    Tragacanth gum

    		Environmental Pollutants Biochemical Assay Reagents Infection Inflammation/Immunology Cancer
    Tragacanth gum is an orally active anionic composite polysaccharide and multifunctional biomaterial. Tragacanth gum exhibits biocompatibility, mucoadhesion and renoprotective effects, and effectively promotes wound closure and tissue healing. Tragacanth gum can be isolated from Astragalus gummifer. Tragacanth gum acts as an emulsifier and drug delivery carrier, and is also widely used in fields such as 3D scaffolds, tissue engineering and green nanoparticle preparation. High doses of Tragacanth gum may induce reversible forestomach squamous epithelial hyperplasia in mice, but show no mutagenic or carcinogenic activity. Tragacanth gum is commonly used in studies related to diseases including systemic candidiasis, rheumatoid arthritis and osteosarcoma .
    Tragacanth gum
  • HY-130354
    Dibutyryl-cGMP sodium
    2 Publications Verification

    Bt2cGMP sodium

    		 Potassium Channel Cardiovascular Disease
    Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ 3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K + channels .
    Dibutyryl-cGMP sodium
  • HY-137273
    Sucrose octasulfate sodium

    		Somatostatin Receptor MMP Inflammation/Immunology
    Sucrose octasulfate sodium, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate sodium stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate sodium exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate sodium can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate sodium can be used in the study of chronic wound healing .
    Sucrose octasulfate sodium
  • HY-134454
    Z-Pro-Pro-CHO

    		Prolyl Endopeptidase (PREP) Parasite Infection
    Z-Pro-Pro-CHO is a potent inhibitor of prolyl oligopeptidase (POP), with extremely high affinity for human prolyl oligopeptidase (HsPOP) (IC50=0.012 μM), and it also effectively inhibits the activity of Schistosoma mansoni prolyl oligopeptidase (SmPOP) (IC50=0.16 μM). Z-Pro-Pro-CHO does not block the phosphorylation of ERK or the production of TNF-α or IFN-γ in immune cells from presensitized mice, nor does it induce harmful phenotypes in cultured Schistosoma mansoni schistosomula. Z-Pro-Pro-CHO only partially inhibits epithelial cell wound healing at extremely high concentrations. Z-Pro-Pro-CHO finds wide application in studies related to schistosomiasis .
    Z-Pro-Pro-CHO
  • HY-108933
    JK-P3

    		VEGFR FGFR Cancer
    JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity .
    JK-P3
  • HY-170366
    VEGFR-2-IN-58

    		VEGFR Apoptosis Cancer
    VEGFR-2-IN-58 (Compound 7b) inhibits VEGFR-2 with an IC50 of 42.5 nM. VEGFR-2-IN-58 displays selective cytotoxicity against cancer cells. VEGFR-2-IN-58 shows cellular growth arrest at the G2/M phase in cancer cells. VEGFR-2-IN-58 induces cancer cells Apoptosis, increasing BAX expression and reducing Bcl2 expression. VEGFR-2-IN-58 inhibits wound closure in cancer cells .
    VEGFR-2-IN-58
  • HY-181126
    G194-0712

    		HDAC Neurological Disease Metabolic Disease Inflammation/Immunology
    G194-0712 is a selective histone deacetylase 5 (HDAC5) activator with an EC50 of 7.96 μM and a Kd of 2.53 μM. G194-0712 restores ACTN4-K417 deacetylation and nuclear import, and increases CSTA expression. G194-0712 accelerates wound closure in chronic wound models, reducing wound area and epithelial gap. G194-0712 can be used for the research of chronic skin wounds, such as diabetic wounds, ischemic wounds, radiation injury wounds .
    G194-0712
  • HY-182450
    WX-293

    		Ser/Thr Protease Cancer
    WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors .
    WX-293
  • HY-137273A
    Sucrose octasulfate

    		MMP Somatostatin Receptor Inflammation/Immunology
    Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing .
    Sucrose octasulfate
  • HY-108933R
    JK-P3 (Standard)

    		Reference Standards VEGFR FGFR Cancer
    JK-P3 (Standard) is the analytical standard of JK-P3 (HY-108933). This product is intended for research and analytical applications. JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor Kinase activity in vitro. JK-P3 has anti-angiogenic activity .
    JK-P3 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: